A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in I Mab stock. As of the latest transaction made, Two Sigma Advisers, LP holds 499,300 shares of IMAB stock, worth $484,321. This represents 0.0% of its overall portfolio holdings.

Number of Shares
499,300
Previous 576,600 13.41%
Holding current value
$484,321
Previous $962,000 35.65%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.03 - $1.72 $79,619 - $132,956
-77,300 Reduced 13.41%
499,300 $619,000
Q2 2024

Aug 14, 2024

SELL
$1.58 - $1.9 $63,990 - $76,950
-40,500 Reduced 6.56%
576,600 $962,000
Q1 2024

May 15, 2024

BUY
$1.54 - $2.37 $89,936 - $138,408
58,400 Added 10.45%
617,100 $1.15 Million
Q4 2023

Feb 14, 2024

BUY
$1.21 - $1.9 $178,112 - $279,680
147,200 Added 35.77%
558,700 $1.06 Million
Q3 2023

Nov 14, 2023

BUY
$1.18 - $3.06 $113,516 - $294,372
96,200 Added 30.51%
411,500 $543,000
Q2 2023

Aug 14, 2023

BUY
$2.95 - $3.85 $202,960 - $264,880
68,800 Added 27.91%
315,300 $942,000
Q1 2023

May 15, 2023

SELL
$3.08 - $7.39 $218,680 - $524,690
-71,000 Reduced 22.36%
246,500 $852,000
Q4 2022

Feb 14, 2023

BUY
$3.22 - $4.86 $277,886 - $419,418
86,300 Added 37.33%
317,500 $1.33 Million
Q3 2022

Nov 14, 2022

BUY
$4.01 - $12.34 $546,563 - $1.68 Million
136,300 Added 143.62%
231,200 $927,000
Q2 2022

Aug 15, 2022

SELL
$8.27 - $18.43 $483,795 - $1.08 Million
-58,500 Reduced 38.14%
94,900 $1.07 Million
Q1 2022

May 16, 2022

BUY
$12.54 - $46.93 $1.92 Million - $7.2 Million
153,400 New
153,400 $2.49 Million

Others Institutions Holding IMAB

About I-Mab


  • Ticker IMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,098,800
  • Market Cap $80.6M
  • Description
  • I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...
More about IMAB
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.